CSIMarket Company Name, Ticker, Suppliers, else..
 
Coeptis Therapeutics Holdings Inc   (NASDAQ: COEP)
Other Ticker:  
 
 
Price: $9.3200 $-0.08 -0.851%
Day's High: $9.4 Week Perf: -0.53 %
Day's Low: $ 9.22 30 Day Perf: 9.65 %
Volume (M): 5 52 Wk High: $ 13.70
Volume (M$): $ 45 52 Wk Avg: $6.32
Open: $9.37 52 Wk Low: $0.14



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 0
 Employees 10
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -10
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Coeptis Therapeutics Holdings Inc
Coeptis Therapeutics Holdings Inc is a pharmaceutical company that specializes in the research, development, and commercialization of innovative therapeutics for various medical conditions. The company aims to improve patient outcomes by focusing on treatments that target unmet medical needs. They may collaborate with other pharmaceutical companies, academic institutions, and research organizations to advance their pipeline of drug candidates. Coeptis Therapeutics Holdings Inc is committed to making a positive impact on global healthcare by providing effective and safe medications to patients worldwide.


   Company Address: 105 Bradford Rd Wexford 15090 PA
   Company Phone Number: 934-6467   Stock Exchange / Ticker: NASDAQ COEP


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -3.04%    
BEAM        5.56% 
CRSP        11.64% 
GILD        0.88% 
MRNA   -1.61%    
NVAX   -5.33%    
• View Complete Report
   



Coeptis Therapeutics Holdings Inc

COEP's Financial Performance in the First Quarter of 2024 Earnings Season



The stock market serves as a crucial indicator of an economy's health, with each company's performance reflecting the overall state of the industry. In this article, we will examine the recent fiscal period of Coeptis Therapeutics Holdings Inc (COEP) and highlight noteworthy facts that shed light on the company's current position in the stock market.
Shifting Fortunes:
One of the key metrics used to evaluate a company's performance is earnings per share (EPS). In the most recent fiscal period, COEP witnessed a significant shift in its financials. The company experienced a loss per share of $-0.08, highlighting a considerable decrease compared to the earnings of $0.00 per share reported in the same quarter a year ago.
This downturn in profitability raises concerns among investors, signaling potential challenges the company may be facing. However, it is important to consider the broader context of COEP's performance to make well-informed investment decisions.
Coeptis Therapeutics Holdings Inc

Coeptis Therapeutics Holdings Inc Surpasses Expectations with $1.3875 Million in Revenue 2.

The stock market has been buzzing with excitement over the recent performance of Coeptis Therapeutics Holdings Inc. The company has achieved remarkable growth in the fiscal period ending December 31, 2023, reporting an impressive revenue of $1.3875 million. This figure represents a significant increase compared to the previous year's revenue of $0.00.
One of the most noteworthy aspects of Coeptis Therapeutics Holdings Inc's performance is its significant improvement in net deficit. In the same financial reporting period a year ago, the company reported a deficit of $-40.249 million. However, in the fiscal period ending December 31, 2023, Coeptis Therapeutics Holdings Inc managed to reduce its deficit to $-4.024 million. This extraordinary improvement showcases the company's ability to effectively manage its finances and make positive strides towards profitability.
Coeptis Therapeutics Holdings Inc

Coeptis Therapeutics Holdings Inc Releases Impressive Q3 2023 Earnings Amidst Strong Business Growth



Investors in Coeptis Therapeutics Holdings Inc were taken by surprise when the company reported modifications to its top-line during the July to September 30, 2023 reporting cycle. Despite positive gains in the company's share performance, there are concerns surrounding Coeptis' operating loss and lack of declared revenue.
During the aforementioned reporting period, Coeptis Therapeutics Holdings Inc experienced an operating loss of $-7.831431 million, which caught investors off guard. The absence of declared revenue adds to the uncertainties surrounding the company's current performance. To provide some context, in the third quarter of 2022, Coeptis Therapeutics Holdings Inc reported an operating loss of $-0.543663 million.
Coeptis Therapeutics Holdings Inc

Coeptis Therapeutics Holdings Inc Struggles with Operating Shortfall, Raises Concerns for Future Growth

Coeptis Therapeutics Holdings Inc is a biotechnology and pharmaceutical company that recently reported an operating shortfall of $-3.638031 million for the fiscal second quarter of 2023. Although the company has not announced its revenue yet, examining the performance of the same period in 2022 reveals an operating shortfall of $-0.852808 million. This suggests that Coeptis Therapeutics Holdings Inc has faced challenges in cultivating profitable revenue sources, as evidenced by the deficit increasing to $-3.113 million between April and June of 2023.
The next financial report from Coeptis Therapeutics Holdings Inc is expected to be released on November 17, 2023. Investors and stakeholders eagerly await these figures to gain insight into the company's financial health and potential future growth.
Coeptis Therapeutics Holdings Inc

Coeptis Therapeutics Sees Break-Even Point Surge To $0.00 per Share in Q1 2023

As a journalist with several years of experience reporting on financial results, I had the opportunity to analyze the latest financial report of Coeptis Therapeutics Holdings Inc for the first quarter of 2023. The report reveals a break-even point of $0.00 per share, which is in stark contrast to the $0.34 per share the company recorded during the same reporting period a year ago. In the prior reporting period, COEP recorded $-0.25 per share.
From the preceding reporting period, the company's earnings per share have increased from $-0.25 per share to $0.00 million. This represents a significant improvement for the company. It is an indication that the company has been working very hard to turn things around.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com